Jan 21, 2025 · KalVista is advancing science to empower everyday lives with innovative oral medicines. KalVista’s mission begins with hereditary angioedema, HAE. Patients & Caregivers

KalVista Pharmaceuticals is a biopharmaceutical company discovering, developing and commercializing oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin …

Find the latest KalVista Pharmaceuticals, Inc. (KALV) stock quote, history, news and other vital information to help you with your stock trading and investing.

KalVista is building a pipeline of novel oral, small molecule protease inhibitors through preclinical and clinical development as potential best-in-class treatments for a range of diseases, …

Jan 23, 2025 · Get a real-time KalVista Pharmaceuticals, Inc. (KALV) stock price quote with breaking news, financials, statistics, charts and more.

Sep 3, 2024 · KalVista announced positive phase 3 data from the KONFIDENT trial for its oral, on-demand therapy, sebetralstat for HAE in February 2024. The Company’s NDA for …

Nov 4, 2024 · KalVista Pharmaceuticals, Inc. is a global pharmaceutical company whose mission is to develop and deliver life-changing oral medicines for people affected by rare diseases with …

Jul 11, 2024 · KalVista Pharmaceuticals, Inc. is a global pharmaceutical company focused on the development and delivery of oral medicines for diseases with significant unmet need. KalVista …

KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with …

Jul 11, 2024 · KalVista is on track for Market Authorization Application submissions to both European Medicines Agency and UK Medicines and Healthcare Products Regulatory Agency …